Clinical Trial

A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a non-Inferiority trial to evaluate efficacy and safety of hydrochloride carliprazine capsules and aripiprazole tablets in treating acute schizophrenia in Chinese adults. 376 patients will be randomizdely assigned in a 1:1 ratio to treatment group and control group. All enrolled subjects will be orally administered with hydrochloride carliprazine capsules or aripiprazole tablets for 6 consecutive weeks.
Trial Details
NCT Number NCT06589817
Lead Sponsor Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Conditions Acute Schizophrenia
Enrollment 376 participants
Start Date 2024-10
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-19